Scott Gottlieb, MD
@scottgottliebmd.bsky.social
Senior Fellow at the American Enterprise Institute. Partner, New Enterprise Associates. Contributor CNBC. 23rd Commissioner of the U.S. FDA. Public boards: Pfizer, Illumina, TempusAI.
Lena Sun at the Washington Post reports that this important team at CDC has been rehired.
These large national cohorts provided data that supported healthcare policymaking across the public and private sectors. They were some of the most important works that only CDC was able to perform - and execute well - as a nationally representative survey.
www.statnews.com/2025/10/14/c...
www.statnews.com/2025/10/14/c...
CDC team running top survey on health and nutrition is laid off
NHANES has collected data on eating patterns, diabetes, and other common diseases for decades. The CDC team that runs it has been fired.
www.statnews.com
October 16, 2025 at 8:40 AM
Lena Sun at the Washington Post reports that this important team at CDC has been rehired.
These large national cohorts provided data that supported healthcare policymaking across the public and private sectors. They were some of the most important works that only CDC was able to perform - and execute well - as a nationally representative survey.
www.statnews.com/2025/10/14/c...
www.statnews.com/2025/10/14/c...
CDC team running top survey on health and nutrition is laid off
NHANES has collected data on eating patterns, diabetes, and other common diseases for decades. The CDC team that runs it has been fired.
www.statnews.com
October 14, 2025 at 7:42 PM
These large national cohorts provided data that supported healthcare policymaking across the public and private sectors. They were some of the most important works that only CDC was able to perform - and execute well - as a nationally representative survey.
www.statnews.com/2025/10/14/c...
www.statnews.com/2025/10/14/c...
Reposted by Scott Gottlieb, MD
"China has no scientific edge over the United States," @scottgottliebmd.bsky.social writes.
"China has only a policy edge, which derives from its deliberate economic strategy."
"China has only a policy edge, which derives from its deliberate economic strategy."
Opinion | With China undermining U.S. biotech, here’s how the FDA can counter
Lower the costs of development for American scientists, too.
wapo.st
September 25, 2025 at 1:25 PM
"China has no scientific edge over the United States," @scottgottliebmd.bsky.social writes.
"China has only a policy edge, which derives from its deliberate economic strategy."
"China has only a policy edge, which derives from its deliberate economic strategy."
My segment on @cnbc.com Squawk Box today on the shift in drug discovery to China, the threat that it poses to the U.S. biotechnology ecosystem, and policy steps that the U.S. FDA can take to level the playing field for early drug discovery.
Dr. Gottlieb on China's biotech strategy: China has become very adept at following U.S. discoveries
YouTube video by CNBC Television
www.youtube.com
September 25, 2025 at 2:57 PM
My segment on @cnbc.com Squawk Box today on the shift in drug discovery to China, the threat that it poses to the U.S. biotechnology ecosystem, and policy steps that the U.S. FDA can take to level the playing field for early drug discovery.
My hit on @cnbc.com today on the new actions to address autism and the need to exercise more judgment and caution
youtu.be/B7t9ryBoBfQ
youtu.be/B7t9ryBoBfQ
Larger trials needed to prove Tylenol, Autism risk correlation: Dr. Scott Gottlieb
YouTube video by CNBC Television
youtu.be
September 23, 2025 at 12:26 AM
My hit on @cnbc.com today on the new actions to address autism and the need to exercise more judgment and caution
youtu.be/B7t9ryBoBfQ
youtu.be/B7t9ryBoBfQ
Reposted by Scott Gottlieb, MD
Measles Death Shows How Virus Can Hide in the Brain for Years www.aol.com/articles/mea...
Measles Death Shows How Virus Can Hide in the Brain for Years
A school-aged child in Los Angeles County has died from a rare but always fatal complication from a measles infection they acquired when they were an infant who was too young to be vaccinated. Expert...
www.aol.com
September 20, 2025 at 11:28 PM
Measles Death Shows How Virus Can Hide in the Brain for Years www.aol.com/articles/mea...
My appearance on #CNBC today about the #CDC’s #ACIP meeting on vaccines, which could bring action by HHS to remove the MMRV vaccine, eliminate the recommendation for Hep B in newborns, and narrow use of Covid vaccines.
CDC vaccine panel to meet this week: Here's what's at stake
YouTube video by CNBC Television
www.youtube.com
September 15, 2025 at 4:49 PM
Reposted by Scott Gottlieb, MD
My CNBC.com segment on implications for pediatric vaccine schedule from recent politics. 2003 saw ~5,000 cases of pertusis, in 2024 there were over 35,000, and for 2025, some models show 70,000+
We risk a return of communicable diseases in children.
www.youtube.com/watch?v=00cI...
We risk a return of communicable diseases in children.
www.youtube.com/watch?v=00cI...
September 8, 2025 at 2:29 PM
My CNBC.com segment on implications for pediatric vaccine schedule from recent politics. 2003 saw ~5,000 cases of pertusis, in 2024 there were over 35,000, and for 2025, some models show 70,000+
We risk a return of communicable diseases in children.
www.youtube.com/watch?v=00cI...
We risk a return of communicable diseases in children.
www.youtube.com/watch?v=00cI...
My CNBC.com segment on implications for pediatric vaccine schedule from recent politics. 2003 saw ~5,000 cases of pertusis, in 2024 there were over 35,000, and for 2025, some models show 70,000+
We risk a return of communicable diseases in children.
www.youtube.com/watch?v=00cI...
We risk a return of communicable diseases in children.
www.youtube.com/watch?v=00cI...
September 8, 2025 at 2:29 PM
My CNBC.com segment on implications for pediatric vaccine schedule from recent politics. 2003 saw ~5,000 cases of pertusis, in 2024 there were over 35,000, and for 2025, some models show 70,000+
We risk a return of communicable diseases in children.
www.youtube.com/watch?v=00cI...
We risk a return of communicable diseases in children.
www.youtube.com/watch?v=00cI...
Dr. Scott Gottlieb reacts to RFK Jr. linking autism to Tylenol
YouTube video by CNBC Television
youtu.be
September 8, 2025 at 10:56 AM
I’ll be coming up on @SquawkCNBC at 6:30 to discuss vaccine safety and public health.
September 8, 2025 at 10:30 AM
I’ll be coming up on @SquawkCNBC at 6:30 to discuss vaccine safety and public health.
Reposted by Scott Gottlieb, MD
📅 Join us Sept. 19 for a conference on #FDA policy reforms aimed at reducing drug development costs and getting valuable new treatments to patients faster.
Speakers: @scottgottliebmd.bsky.social, Janet Woodcock, Ken Drazan, Lowell Schiller & more
➡️Registration: schaeffer.usc.edu/event/reform...
Speakers: @scottgottliebmd.bsky.social, Janet Woodcock, Ken Drazan, Lowell Schiller & more
➡️Registration: schaeffer.usc.edu/event/reform...
August 20, 2025 at 6:52 PM
📅 Join us Sept. 19 for a conference on #FDA policy reforms aimed at reducing drug development costs and getting valuable new treatments to patients faster.
Speakers: @scottgottliebmd.bsky.social, Janet Woodcock, Ken Drazan, Lowell Schiller & more
➡️Registration: schaeffer.usc.edu/event/reform...
Speakers: @scottgottliebmd.bsky.social, Janet Woodcock, Ken Drazan, Lowell Schiller & more
➡️Registration: schaeffer.usc.edu/event/reform...
My editorial in JAMA Health Forum: To support the academic research enterprise, we should pursue regulatory reforms that enable institutions to advance more of their discoveries to patients and, in doing so, capture more economic value of innovations they achieve
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Securing America’s Pharmaceutical Innovation Edge
This JAMA Forum discusses challenges to the US’s standing as a global leader in biomedical innovation from China, in the context of recent reductions in funding for biomedical research by the federal ...
jamanetwork.com
August 21, 2025 at 6:18 PM
My editorial in JAMA Health Forum: To support the academic research enterprise, we should pursue regulatory reforms that enable institutions to advance more of their discoveries to patients and, in doing so, capture more economic value of innovations they achieve
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
CSL, a major manufacturer of flu vaccine, is spinning off its entire vaccine unit and cutting up to 15% of its staff. Influenza vaccine uptake is off by about 10%
www.wsj.com/business/csl...
www.wsj.com/business/csl...
CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure
Australia-listed CSL, which has a significant portion of its business in the U.S., announced its intention to simplify its operating structure amid a challenging and volatile environment.
www.wsj.com
August 19, 2025 at 4:31 PM
CSL, a major manufacturer of flu vaccine, is spinning off its entire vaccine unit and cutting up to 15% of its staff. Influenza vaccine uptake is off by about 10%
www.wsj.com/business/csl...
www.wsj.com/business/csl...
Reposted by Scott Gottlieb, MD
From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force
insights.citeline.com/pink-sheet/a...
insights.citeline.com/pink-sheet/a...
US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited
The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-for...
insights.citeline.com
July 26, 2025 at 11:13 PM
From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force
insights.citeline.com/pink-sheet/a...
insights.citeline.com/pink-sheet/a...
From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force
insights.citeline.com/pink-sheet/a...
insights.citeline.com/pink-sheet/a...
US FDA’s Biologics Center Departures Grew Before More Than 100 RIFs Exited
The Center for Biologics Evaluation and Research saw departures far outnumber new hires in the second and third quarters of FY 2025, before more than 100 people left July 14 after the reduction-in-for...
insights.citeline.com
July 26, 2025 at 11:13 PM
From Pink Sheet on continued departures from FDA’s biologics division and challenges backfilling openings. FDA biologics center reported 106 departures from Jan. 1 to June 30. These numbers don’t include the 100-150 who were part of the reduction-in-force
insights.citeline.com/pink-sheet/a...
insights.citeline.com/pink-sheet/a...
FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers
insights.citeline.com/pink-sheet/a...
insights.citeline.com/pink-sheet/a...
July 26, 2025 at 1:57 PM
FDA’s cancer review team overseeing breast and gynecological products has lost about 1/3 of its medical review staff and the malignant heme group will lose about 2/3 of its medical review staff—all to voluntary resignations clustered among seasoned reviewers
insights.citeline.com/pink-sheet/a...
insights.citeline.com/pink-sheet/a...
Reposted by Scott Gottlieb, MD
My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.
Dr. Scott Gottlieb on HHS Secretary RFK Jr.'s newly appointed vaccine advisory panel
YouTube video by Face the Nation
youtu.be
June 30, 2025 at 2:32 AM
My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.
My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.
Dr. Scott Gottlieb on HHS Secretary RFK Jr.'s newly appointed vaccine advisory panel
YouTube video by Face the Nation
youtu.be
June 30, 2025 at 2:32 AM
My segment today on CBS.com Face the Nation on the recent CDC vaccine advisory committee meeting.
Reposted by Scott Gottlieb, MD
My segment today on cnbc.com on the CDC’s ACIP meeting.
Dr. Scott Gottlieb on CDC's new vaccine advisory board: The consequences will be felt for years
YouTube video by CNBC Television
youtu.be
June 26, 2025 at 2:33 PM
My segment today on cnbc.com on the CDC’s ACIP meeting.
My segment today on cnbc.com on the CDC’s ACIP meeting.
Dr. Scott Gottlieb on CDC's new vaccine advisory board: The consequences will be felt for years
YouTube video by CNBC Television
youtu.be
June 26, 2025 at 2:33 PM
My segment today on cnbc.com on the CDC’s ACIP meeting.
Reposted by Scott Gottlieb, MD
My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com
June 1, 2025 at 2:31 PM
My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com
My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com
June 1, 2025 at 2:31 PM
My Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight the success. Recently, however, the FDA review team enabling these approvals was disbanded, and it may undo that historic progress. @statnews.com
Reposted by Scott Gottlieb, MD
My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress
Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements
The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang for the taxpayers’ buck, writes former FDA Commissioner Scott Gottlieb.
www.statnews.com
May 29, 2025 at 8:15 PM
My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress
My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress
Former FDA commissioner: ‘Cost-cutting’ may undo one of Trump’s best drug pricing achievements
The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang for the taxpayers’ buck, writes former FDA Commissioner Scott Gottlieb.
www.statnews.com
May 29, 2025 at 8:15 PM
My STAT News Op Ed: President Trump often touted that his first administration approved more generic drugs than any in history. He had good reason to highlight that success. Recently, however, the FDA team enabling these approvals was disbanded. It may undo that historic progress